Find XO: ArtBlood Aims to Manufacture Blood in Factories (venturesquare.net)
Writing language: Korean Read in the original language
Summary / Read source ↗
- ArtBlood, developing ex-vivo red blood cell production technology, has been selected for the '2026 Supergap Startup Project.'
- Funding to continue research is welcome, but the key issue is whether the blood can be reliably mass-produced at hospital-grade quality.
- In biotech startups, attention focuses more on how far the costly verification during clinical and production stages can be completed than on the total amount of grants.